A

Aquestive Therapeutics Inc
NASDAQ:AQST

Watchlist Manager
Aquestive Therapeutics Inc
NASDAQ:AQST
Watchlist
Price: 4.57 USD -5.38% Market Closed
Market Cap: 416.1m USD
Have any thoughts about
Aquestive Therapeutics Inc?
Write Note

Aquestive Therapeutics Inc
Cash & Cash Equivalents

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Aquestive Therapeutics Inc
Cash & Cash Equivalents Peer Comparison

Comparables:
JNJ
BMY
PFE
MRK
LLY

Competitive Cash & Cash Equivalents Analysis
Latest Figures & CAGR of Competitors

Company Cash & Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
A
Aquestive Therapeutics Inc
NASDAQ:AQST
Cash & Cash Equivalents
$89.9m
CAGR 3-Years
38%
CAGR 5-Years
32%
CAGR 10-Years
N/A
Johnson & Johnson
NYSE:JNJ
Cash & Cash Equivalents
$8.2B
CAGR 3-Years
20%
CAGR 5-Years
15%
CAGR 10-Years
-5%
Bristol-Myers Squibb Co
NYSE:BMY
Cash & Cash Equivalents
$7.9B
CAGR 3-Years
-16%
CAGR 5-Years
-24%
CAGR 10-Years
5%
Pfizer Inc
NYSE:PFE
Cash & Cash Equivalents
$1.1B
CAGR 3-Years
-19%
CAGR 5-Years
-18%
CAGR 10-Years
-8%
Merck & Co Inc
NYSE:MRK
Cash & Cash Equivalents
$14.6B
CAGR 3-Years
13%
CAGR 5-Years
13%
CAGR 10-Years
3%
Eli Lilly and Co
NYSE:LLY
Cash & Cash Equivalents
$3.4B
CAGR 3-Years
-4%
CAGR 5-Years
17%
CAGR 10-Years
1%

See Also

What is Aquestive Therapeutics Inc's Cash & Cash Equivalents?
Cash & Cash Equivalents
89.9m USD

Based on the financial report for Jun 30, 2024, Aquestive Therapeutics Inc's Cash & Cash Equivalents amounts to 89.9m USD.

What is Aquestive Therapeutics Inc's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 5Y
32%

Over the last year, the Cash & Cash Equivalents growth was 300%. The average annual Cash & Cash Equivalents growth rates for Aquestive Therapeutics Inc have been 38% over the past three years , 32% over the past five years .

Back to Top